Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 1
2012 2
2013 2
2014 1
2015 4
2016 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Casulo C, et al. Among authors: shewade a. Lancet Haematol. 2022 Apr;9(4):e289-e300. doi: 10.1016/S2352-3026(22)00033-3. Lancet Haematol. 2022. PMID: 35358443 Free PMC article.
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
McGough SF, Shamas N, Wang J, Jaber M, Swarup B, Blanchet Zumofen MH, Lautié B, Parreira J, Wei MC, Shewade A. McGough SF, et al. Among authors: shewade a. Leuk Lymphoma. 2023 Dec;64(14):2269-2278. doi: 10.1080/10428194.2023.2262066. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37840271
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Maurer MJ, et al. Among authors: shewade a. Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737. Online ahead of print. Haematologica. 2023. PMID: 38031804 Free article.
Cost-effectiveness of gene-expression profiling for tumor-site origin.
Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Hornberger J, et al. Among authors: shewade a. Value Health. 2013 Jan-Feb;16(1):46-56. doi: 10.1016/j.jval.2012.09.005. Value Health. 2013. PMID: 23337215 Free article.
Cost consequences of HIV-associated lipoatrophy.
Hornberger J, Rajagopalan R, Shewade A, Loutfy MR. Hornberger J, et al. Among authors: shewade a. AIDS Care. 2009 May;21(5):664-71. doi: 10.1080/09540120802511851. AIDS Care. 2009. PMID: 19444676
16 results